VINORELBINE PIERRE FABRE vinorelbine 80mg (as tartrate) capsule blister pack

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Principio attivo:

vinorelbine tartrate, Quantity: 110.8 mg (Equivalent: vinorelbine, Qty 80 mg)

Commercializzato da:

Pierre Fabre Australia Pty Ltd

Forma farmaceutica:

Capsule, soft

Composizione:

Excipient Ingredients: ethanol; purified water; glycerol; macrogol 400; Gelatin; iron oxide yellow; titanium dioxide; medium chain triglycerides; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; hypromellose; propylene glycol; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal

Via di somministrazione:

Oral

Confezione:

1 tablet

Tipo di ricetta:

(S4) Prescription Only Medicine

Indicazioni terapeutiche:

Non-small cell lung cancer: VINORELBINE PIERRE FABRE is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,Breast cancer: VINORELBINE PIERRE FABRE is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Dettagli prodotto:

Visual Identification: pale yellow, soft capsule printed N80.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 30 Months; Container Temperature: Store at 2 to 8 degrees Celsius

Stato dell'autorizzazione:

Registered

Data dell'autorizzazione:

2005-05-31